Cervical Cancer Clinical Trials

About Cervical Cancer trials

Cervical cancer is HPV-driven in nearly all cases (>95%), with squamous cell carcinoma the most common histology and adenocarcinoma a smaller subset. PD-L1 (CD274) status, measured by combined positive score (CPS), gates immunotherapy trials and is foundational for the post-KEYNOTE-826 standard of chemo + bevacizumab + pembrolizumab in metastatic disease. PIK3CA mutations are common in cervical cancer and gate PI3K inhibitor trials. HER2 (ERBB2) amplification is rare but actionable for HER2-targeted ADC trials when present.

Active trials in cervical cancer split by stage and treatment line. Locally advanced trials test additions to or alternatives to cisplatin-based chemoradiation, with IO consolidation an active area following recent practice-changing trials. Metastatic first-line trials center on the chemo + bevacizumab + IO standard, with novel additions and substitutions in development. Recurrent / metastatic later-line trials test tisotumab vedotin (a tissue factor-directed ADC, now approved after progression on chemotherapy) and combinations, IO rechallenge, and HER2-targeted ADCs for HER2-amplified tumors. HPV-targeted trials test tumor-infiltrating lymphocyte (TIL) therapy, HPV-specific T-cell receptor (TCR-T) therapy, and HPV vaccine approaches because of the strong viral driver. Fertility-sparing trials in early-stage disease test less radical surgical and radiation approaches for younger patients.

When you reach trial screening for cervical cancer, expect questions about stage, PD-L1 status, and prior platinum and IO exposure. Stage and treatment intent (locally advanced vs metastatic vs recurrent) determines which trial set applies. Histology (squamous cell carcinoma vs adenocarcinoma vs adenosquamous vs other) gates some trials. PD-L1 CPS with cutoffs that vary by trial design (often CPS ≥1 for IO trials). Prior platinum chemoradiation status. Prior IO exposure for IO-rechallenge or post-IO trials. Prior tisotumab vedotin exposure has become a defining filter as TV moves to earlier lines. HER2 status by IHC or FISH for HER2-amplified trials. HIV status for HIV-associated cervical cancer trials given the higher prevalence in HIV-positive women. Performance status, with most trials accepting ECOG 0-1.

Biomarkers tested in Cervical Cancer trials

These are the molecular markers most commonly required or evaluated in Cervical Cancer eligibility criteria. OncoMatch extracts them from each trial's protocol and matches them against your test results.